Publications (copy) - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals.

Vendruscolo et al. • 2015 • J Clin Invest. 2015;125(8):3193-7.

Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome.

Yuen et al. • 2015 • Endocr Pract. 2015;21(10):1087-92.

Mifepristone and Cushing syndrome: A commentary.

Kennedy L. • 2015 • Endocr Pract. 2015;21(10):1175-7.

Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study

Morelli et al • 2014 • J Clin Endocrinol Metab.

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study

Di Dalmazi et al • 2014 • Lancet Diabetes Endocrinol.

Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas

Debono et al • 2014 • J Clin Endocrinol Metab.

The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice.

Meyer et al. • 2014 • J Steroid Biochem Mol Biol. 2014 Sep;143:40-8.

Age- and sex-dependent effects of early life stress on hippocampal neurogenesis.

Loi et al. • 2014 • Front Endocrinol (Lausanne). 2014;5:13.

A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone.

Fleseriu et al. • 2013 • Endocr Pract. 2013;19(2):313-26.

Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

Baglietto-Vargas et al. • 2013 • Biol Psychiatry. 2013;74(5):357-66.